Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial

@article{Vermeire2014EtrolizumabAI,
  title={Etrolizumab as induction therapy for ulcerative colitis: a randomised, controlled, phase 2 trial},
  author={S{\'e}verine Vermeire and Sharon O’Byrne and Mary E. Keir and Marna B. Williams and Timothy Lu and John C. Mansfield and Christopher Andrew Lamb and Brian G. Feagan and Juli{\'a}n Pan{\'e}s and Azucena Salas and Daniel C. Baumgart and Stefan Schreiber and Iris Dotan and William J. Sandborn and Gaik Wei Tew and Diana Luca and Meina T Tang and Lauri Diehl and Jeffrey Eastham‐Anderson and Gert de Hertogh and Clémentine Perrier and Jackson G. Egen and John A. Kirby and Gert Van Van Assche and Paul J. Rutgeerts},
  journal={The Lancet},
  year={2014},
  volume={384},
  pages={309-318}
}
View on Elsevier
doi.org
366 Citations
Highly Influential Citations
12
Background Citations
71
Methods Citations
14
Results Citations
7

Figures and Tables from this paper

366 Citations

Etrolizumab in moderate-to-severe ulcerative colitis
Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
Efficacy and Safety of Abrilumab in a Randomized, Placebo-Controlled Trial for Moderate-to-Severe Ulcerative Colitis.
TLDR
Abrilumab treatment for 8 weeks induced remission, clinical response, and mucosal healing in patients with moderate-to-severe ulcerative colitis in a randomized, phase 2b, placebo-controlled, double-blind study.
Etrolizumab for induction of remission in ulcerative colitis.
TLDR
The overall quality of evidence for the clinical remission outcomes was moderate and the efficacy and safety of etrolizumab for induction of remission in ulcerative colitis was assessed.
Etrolizumab versus infliximab in the treatment of induction phase of ulcerative colitis: A systematic review and indirect comparison
Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial
Eldelumab [Anti-IP-10] Induction Therapy for Ulcerative Colitis: A Randomised, Placebo-Controlled, Phase 2b Study.
TLDR
The primary endpoint of clinical remission was not achieved with induction treatment with eldelumab 15 or 25 mg/kg in patients with UC, and trends towards clinical remission and response were observed in the overall population and were more pronounced in anti-TNF naïve patients.
...
...

References

SHOWING 1-10 OF 39 REFERENCES
Infliximab for induction and maintenance therapy for ulcerative colitis.
TLDR
Patients with moderate-to-severe active ulcerative colitis treated with infliximab at weeks 0, 2, and 6 and every eight weeks thereafter were more likely to have a clinical response at weeks 8, 30, and 54 than were those receiving placebo.
Vedolizumab as induction and maintenance therapy for ulcerative colitis.
TLDR
Vedolizumab was more effective than placebo as induction and maintenance therapy for ulcerative colitis and the frequency of adverse events was similar in the vedolIZumab and placebo groups.
Treatment of ulcerative colitis with a humanized antibody to the alpha4beta7 integrin.
TLDR
In this short-term study, MLN02 was more effective than placebo for the induction of clinical and endoscopic remission in patients with active ulcerative colitis.
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
TLDR
The favourable short-term safety profile and preliminary efficacy findings for PF-00547,659 in this first-in-human study pave the way for further investigation in larger trials, to establish the role of PF-00928681 in ulcerative colitis treatment.
Administration of mAb Against αEβ7 Prevents and Ameliorates Immunization-Induced Colitis in IL-2−/− Mice
TLDR
The above findings demonstrate that the onset and maintenance of inflammatory bowel disease depends on the colonic localization of lamina propria CD4 + lymphocytes expressing α E β 7.
A reproducible grading scale for histological assessment of inflammation in ulcerative colitis
TLDR
A histological activity system was developed for ulcerative colitis that showed good reproducibility and modest agreement with the endoscopic grading system which it complemented and has potential value both clinically and in clinical trials.
A unique subpopulation of CD4+ regulatory T cells controls wasting disease, IL‐10 secretion and T cell homeostasis
TLDR
It is shown that CD103+CD25+CD4+ T cells (that control inflammatory bowel disease) are highly enriched in gut‐associated lymphoid tissue and have unique functional properties.
Human intestinal epithelial cells promote the differentiation of tolerogenic dendritic cells
TLDR
A population of tolerogenic CD103+ DCs was identified in the human gut that probably differentiate in response to IEC-derived factors and drive Treg cell development.
Mucosal T lymphocyte numbers are selectively reduced in integrin alpha E (CD103)-deficient mice.
TLDR
It is suggested that alpha E beta 7 is involved in the expansion/recruitment of TCR alpha beta+ CD8+ IEL following microbial colonization and lamina propria T lymphocyte numbers were diminished in alpha E-deficient mice.
...
...